// App-Quantinova.ai

BSH2020‐EP‐083 : Btk inhibitors ibrutinib and acalabrutinib impair FcγRIIa‐mediated responses of healthy donor platelets and chronic lymphocytic leukaemia platelets to bacteria

Researchers

Presenter

  • L. Naylor-Adamson

Principal Investigators

  • Z. Booth

  • J. Jarvis

  • S. Hart

  • D. Allsup

  • M. Arman

Medical Centers

  • Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, University of Hull

  • Department of Biomedical Sciences, University of Hull, Hull, UK

  • Respiratory Research Group, Hull York Medical School, University of Hull

  • Department of Haematology, Queens Centre for Oncology and Haematology, Castle Hill Hospital, Hull and East Yorkshire Hospitals NHS Trust, Hull, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Obstetrics/Gynecology

Disease

  • Chronic Lymphocytic Leukemia

  • Twin-reversed arterial perfusion

Biomarkers

  • Platelet Factor 4

  • Immunoglobulin G

  • Triiodothyronine receptor auxiliary protein

Drug/Treatment

  • ACP-196

  • Ibrutinib

  • Evithrom

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved